atezolizumab Durvalumab Durvalumab amfinzi)is a human immunoglobulin gi kappa)monoclonal antibody that blocks the interaction of programmed cell death ligand 1(PD-L1)with the PD-1 and CD80(B7.1)molecules.Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: .have disease progression during or following platinum-containing chemotherapy. Ipilimumab Ipilimumab(Yervoy)is a human IgG1 antibody that binds the surface protein CTLA4.In normal physiology T receptor CD28 bnding to CaoorC prevenin RdDa6pmotei therefore negatively regulates the activation of T-c Active cytotoxic T-cells are required for the immune system to attack melanoma cells.Normally inhibited e an en ectoytoroxicTcs to increase te anti-um Regulatory T Nivolumab Ofatumumab Ofatumumab is Unlike rituximab,which binds to a large loop of the CD20 protein,ofatumumab binds to a separate,small loop This may explain their different characteristics.Compared to ritu pcndeatcotoictvyatalomcrdoewlGsmnmunogentaWohatumumabricscomolene Pembrolizumab Pembrolizumab is ap ved for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression as determined by an FDA-approved test. Rituximab CD20 is relatively unknown,CD20 may be a calcium channel involved in B-cell activation.The antibody's mode of action is prmarily through t induction OT ADC B-cells to ch Cytokine therapy